Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 9, Issue 7 (2020)

Yiqi Fumai Lyophilized Injection Ameliorates the Vasopressin-Induced Angina Pectoris Associated with the NF-κB Pathway

Author(s):
Xiangbo Gou, Haodong Zhao, Meixu Wan, Zhi Li and Dekun Li
Abstract:
The aim of our study was to research the protective effect of YQFM on the vasopressin-induced rat anginal model and to explore the underlying pathway. The rat anginal model was established successfully by vasopressin injection. The cardiac function, tissue morphology and myocardial enzymes in the serum were detected to evaluate the cardiac injury. The pro-inflammatory factor such as TNF-α and IL-6, as well as the involved NF-κB pathway were detected through western blot. The anginal rats presented a depressed ST-segment in ECG accompanied with disordered cardiac function, tissue morphology and myocardial enzyme levels in the serum, which were all attenuated by the YQFM treatment. Moreover, YQFM can also inhibit the TNF-a and IL-6 protein levels, further down regulate the NF-κB signaling pathway in the anginal rats. These findings suggest that YQFM ameliorates the cardiac injury in the rat anginal model associated with the NF-κB signaling pathway.
Pages: 553-560  |  336 Views  137 Downloads


The Pharma Innovation Journal
How to cite this article:
Xiangbo Gou, Haodong Zhao, Meixu Wan, Zhi Li, Dekun Li. Yiqi Fumai Lyophilized Injection Ameliorates the Vasopressin-Induced Angina Pectoris Associated with the NF-κB Pathway. Pharma Innovation 2020;9(7):553-560.

Call for book chapter